Telmisartan, Amlodipine and Flow Mediated Dilation (TEAMSTAprotect)

• ClinicalTrials.gov Identifier: NCT01180205
• Recruitment Status: Unknown
• First Posted: August 12, 2010
• Last Update Posted: July 12, 2011
• Sponsor: Johannes Gutenberg University Mainz
• Information provided by: Johannes Gutenberg University Mainz

Study Description

Brief Summary:

To show superior effects of the combination Telmisartan and Amlodipine (T and A) vs Olmesartan and Hydrochlorothiazide (O and HCTZ) on endothelial dysfunction as measured by flow mediated dilation (FMD) in hypertensive at risk patients beyond bloodpressure BP (equal BP in both arms; target BP <140/90 mmHg (<130/80 mmHg for renally impaired and/ or diabetic patients). To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness and carotid atherosclerotic plaques.

Condition or disease	Intervention/treatment	Phase
Hypertension	Drug: Telmisartan; Drug: Amlodipine; Drug: Olmesartan medoxomil; Drug: Hydrochlorothiazide	Phase 4

Detailed Description:

This is a Phase IV, randomised, double-blind, forced- titration, active controlled, mono-center study to primarily compare the effects on endothelial function of the combination of telmisartan and amlodipine versus olmesartan and hydrochlorothiazide in hypertensive patients at risk beyond blood pressure. Additionally, key secondary endpoints for this trial are the changes in plaque and intima media complex echogenicity and the change in arterial stiffness after 26 weeks of treatment.

576 patients will be included in the study after a screening period of two weeks and then randomised in one of the two treatment groups. Pretreatment with ARBs, ACE-Inhibitors, amlodipine and diuretics will be stopped last day before visit 2. At visit 2 the treatment with either telmisartan and amlodipine or olmesartan and hydrochlorothiazide starts, so that no medication is stopped without having been replaced by the study medication. After two weeks treatment all patients will be up-titrated and having the maintenance dose for the following 24 weeks. The trial will be performed at one center in Germany with access to patients with hypertension. Patients will be recruited from the Department of Cardiology of the university Mainz. There will be a promotion flyer and an information booklet about the study for cardiologists practicising near Mainz, who like to sent their patient to the study center. Sponsor of the trial is the university Mainz.

Stefan Blankenberg, MD has been designated as Principal Investigator for this national, mono-center trial.

The study will be completed when the last patient had his last visit and the telephone follow - up two weeks later will be performed. This latest patient contact is defined as end of trial.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 576 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure
• Study Start Date: August 2010
• Estimated Primary Completion Date: October 2011
• Estimated Study Completion Date: October 2011

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: T/A; Telmisartan + Amlopidpine	Drug: Telmisartan; Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks); Other Name: MICARDIS® (Telmisartan); Drug: Amlodipine; Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks; Other Name: Norvasc
Active Comparator: O/HCT; Olmesartan + Hydrochlorothiazide	Drug: Olmesartan medoxomil; Olmesartan 40 mg po for 26 weeks; Other Name: Olmetec; Drug: Hydrochlorothiazide; HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks

Outcome Measures

Primary Outcome Measures :

1. FMD flow mediated dilation [ Time Frame: baseline ]
   The overall mean improvement following 26 weeks of treatment in FMD as measured by the change from Visit 2 for T80/A10 is equal to O40/H25.
2. FMD [ Time Frame: after 26 weeks ]
   The overall mean improvement following 26 weeks of treatment in FMD as measured by the change from Visit 2 for T80/A10 is equal to O40/H25.

Secondary Outcome Measures :

1. Echogenicity [ Time Frame: baseline ]
   To investigate the effects of T and A vs O and HCTZ on grayscale median of carotid atherosclerotic plaques
2. arterial stiffness [ Time Frame: baseline ]
   To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness
3. arterial stiffness [ Time Frame: after 26 weeks ]
   To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness
4. Echogenicity [ Time Frame: after 26 weeks ]
   To investigate the effects of T and A vs O and HCTZ on grayscale median of carotid atherosclerotic plaques

Eligibility Criteria

• Ages Eligible for Study: 35 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation.
• Age 35 and older.
• Male and female, treated and treatment-naive patients with uncontrolled hypertension (defined as 20/10 mmHg above target BP of <140/90 mmHg [<130/80 mmHg for renally impaired and/ or diabetics patients])
• Male and female treated patients with controlled hypertension (defined as target BP < 140/90 mmHg [ < 130/80 mmHg for renally impaired and/ or diabetics patients])
• > 3 cardiovascular risk factors CVRFs and/or metabolic syndrome and/or diabetes mellitus and/or end organ damage

Exclusion Criteria:

1. Pretreatment with Telmisartan within the last 3 months.
2. Pretreatment with Amlodipine, Diuretics and AT1Blocker/ACEInhibitor within the last 3 months
3. Myocardial infarction within last 6 months.
4. Previous stroke or hemodynamically relevant stenosis of carotic arteria (>70%).
5. Previous cardial or peripheral bypass surgery within last 6 months.
6. PAD stadium III - IV n.F.
7. Chronic heart failure NYHA III- IV.
8. Unstable angina.
9. Known intolerance to angiotensin receptor blockers, diuretics or dihydropyridine calcium channel blocker.

10. Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who:

    1. are not surgically sterile; or
    2. are nursing, or
    3. are pregnant, or

    4. are of childbearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the trial.

       The only acceptable methods of birth control are:

    5. Intra-Uterine Device (IUD)
    6. Oral
    7. implantable or injectable contraceptives
    8. Estrogen patch
    9. Hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study
11. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.
12. Known or suspected secondary hypertension (e.g., renal artery stenosis or phaeochromocytoma)
13. Mean in-clinic seated cuff SBP ≥180 mmHg and/or DBP ≥110 mmHg
14. Renal dysfunction as defined by the following laboratory parameters:
15. Serum creatinine >3.0 mg/dL (or >265 μmol/L) and/or known estimated creatinine clearance of <30 ml/min and/or clinical markers of severe renal impairment.
16. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney
17. Clinically relevant hypokalemia or hyperkalemia (i.e., <3.0 or >5.5 mEq/L, may be rechecked for suspected error in result)
18. Uncorrected sodium or volume depletion
19. Primary aldosteronism
20. Hereditary fructose intolerance
21. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency
22. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator
23. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
24. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥10%
25. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists
26. History of drug or alcohol abuses within six months prior to signing the informed consent form
27. Concomitant administration of any medications known to affect BP, except medications allowed by the protocol
28. Any investigational drug therapy within one month of signing the informed consent
29. Known contraindication to any component of the trial drugs (telmisartan, amlodipine, olmesartan, hydrochlorothiazide)
30. History of non-compliance or inability to comply with prescribed medications or protocol procedures
31. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication

Contacts and Locations

Locations

Germany

Universitätsmedizin Mainz

Mainz, Rheinland-Pfalz, Germany, 55131

Sponsors and Collaborators

Johannes Gutenberg University Mainz

Investigators

• Principal Investigator: Stefan Blankenberg, Prof.Dr.med.; Universitätsmedizin Mainz, II.Medizinische Klinik

More Information

• Responsible Party: Prof.Dr.med.S.Blankenberg, Departement for cardiology
• ClinicalTrials.gov Identifier: NCT01180205
• Other Study ID Numbers: 2009-017010-68
• First Posted: August 12, 2010
• Last Update Posted: July 12, 2011
• Last Verified: April 2010

Keywords provided by Johannes Gutenberg University Mainz:

FMD; hypertension; Telmisartan; Amlodipine

Additional relevant MeSH terms:

Hypertension; Vascular Diseases; Cardiovascular Diseases; Amlodipine; Hydrochlorothiazide; Telmisartan; Olmesartan; Olmesartan Medoxomil; Antihypertensive Agents; Calcium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs; Vasodilator Agents; Diuretics; Natriuretic Agents; Sodium Chloride Symporter Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists